# OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
Canonical URL: https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chief-medical-officer-dff9c1eb
Ticker: OKYO
Company: OKYO Pharma
Source: OKYO Pharma
Published: 2026-07-22 11:00 EST
## Summary

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing...

## Article Body
OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com .

For further inquiries:

OKYO Pharma Ltd Paul Spencer Business Development and Investor Relations +44 (0) 207 495 2379 Email: info@okyopharma.com
## Recent Company News
- 2026-07-28 11:00 EST — [OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer](https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chief-scientific-officer-63ff975a) — Source: OKYO Pharma
- 2026-07-27 11:00 EST — [OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026](https://biopharmsignal.com/news/OKYO/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026-75cdfd34) — Source: OKYO Pharma
- 2026-07-23 16:00 EST — [OKYO Pharma Announces Purchase of Shares by Director](https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-director-aba58ba0) — Source: OKYO Pharma
- 2026-07-23 11:00 EST — [OKYO Pharma Announces Purchase of Shares by Chief Executive Officer](https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chief-executive-officer-c26c1c2c) — Source: OKYO Pharma
- 2026-07-22 16:00 EST — [OKYO Pharma Announces Purchase of Shares by Chairman](https://biopharmsignal.com/news/OKYO/okyo-pharma-announces-purchase-of-shares-by-chairman-991103cf) — Source: OKYO Pharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)